Unknown PHASE2 INTERVENTIONAL 1-arm NCT03611231

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial

Sponsor: Hebei Medical University Fourth Hospital

Conditions Experimental Tumor

Interventions Chidamide

Updated 5 times since 2018 Last updated: Aug 1, 2018 Started: Sep 1, 2018 Primary completion: Dec 30, 2020 Completion: Dec 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03611231, this PHASE2 trial focuses on Experimental Tumor and remains ongoing. Sponsored by Hebei Medical University Fourth Hospital, it has been updated 5 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2
Sep 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Medical University Fourth Hospital
Peking University
Peking University International Hospital

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China